Evidence map›Paper›PMID 27534266›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2017

Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear.

Davide D'Amico, Thomas Gener, Maria Martínez de Lagrán, Maria V Sanchez-Vives, Mónica Santos, Mara Dierssen

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Davide D'AmicoSystems Biology Programme, Centre for Genomic Regulation (CRG)/Barcelona Biomedical Research Park, Barcelona, Spain.
Thomas GenerSystems Biology Programme, Centre for Genomic Regulation (CRG)/Barcelona Biomedical Research Park, Barcelona, Spain.ORCID 0000-0001-9209-9228
Maria Martínez de LagránSystems Biology Programme, Centre for Genomic Regulation (CRG)/Barcelona Biomedical Research Park, Barcelona, Spain.
Maria V Sanchez-VivesSystems Neuroscience, IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain.
Mónica SantosSystems Biology Programme, Centre for Genomic Regulation (CRG)/Barcelona Biomedical Research Park, Barcelona, Spain.
Mara DierssenSystems Biology Programme, Centre for Genomic Regulation (CRG)/Barcelona Biomedical Research Park, Barcelona, Spain.ORCID 0000-0003-0853-6865
Universitat Pompeu Fabra · ESInstitució Catalana de Recerca i Estudis Avançats · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inability to properly extinguish fear memories constitutes the foundation of several anxiety disorders, including panic disorder. Recent findings show that boosting prefrontal cortex synaptic plasticity potentiates fear extinction, suggesting that therapies that augment synaptic plasticity could prove useful in rescue of fear extinction impairments in this group of disorders. Previously, we reported that mice with selective deregulation of neurotrophic tyrosine kinase receptor, type 3 expression (TgNTRK3) exhibit increased fear memories accompanied by impaired extinction, congruent with an altered activation pattern of the amygdala-hippocampus-medial prefrontal cortex fear circuit. Here we explore the specific role of neurotrophin 3 and its cognate receptor in the medial prefrontal cortex, and its involvement in fear extinction in a pathological context. In this study we combined molecular, behavioral, in vivo pharmacology and ex vivo electrophysiological recordings in TgNTRK3 animals during contextual fear extinction processes. We show that neurotrophin 3 protein levels are increased upon contextual fear extinction in wild-type animals but not in TgNTRK3 mice, which present deficits in infralimbic long-term potentiation. Importantly, infusion of neurotrophin 3 to the medial prefrontal cortex of TgNTRK3 mice rescues contextual fear extinction and ex vivo local application improves medial prefrontal cortex synaptic plasticity. This effect is blocked by inhibition of extracellular signal-regulated kinase phosphorylation through peripheral administration of SL327, suggesting that rescue occurs via this pathway. Our results suggest that stimulating neurotrophin 3-dependent medial prefrontal cortex plasticity could restore contextual fear extinction deficit in pathological fear and could constitute an effective treatment for fear-related disorders.

Indexed as

FearAnimalsDisease Models, AnimalExtinction, PsychologicalExtracellular Signal-Regulated MAP KinasesFemaleLong-Term PotentiationMaleMice, Inbred C57BLMice, TransgenicNeuronal PlasticityNeurotrophin 3Phobic DisordersPrefrontal CortexPyramidal CellsReceptor, trkCExtracellular Signal-Regulated MAP KinasesNeurotrophin 3Receptor, trkC

Identifiers

PMID27534266
PMCPMC5399232
OpenAlexW2512692201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.